Basic Information
HyperRAB Solution for Infiltration & Intramuscular Injection
INJECTION
Regulatory Information
SIN09657P
February 26, 1998
Prescription Only
Therapeutic
INTRAMUSCULAR, INFILTRATION
August 10, 2023
June 3, 2025
XJ06BB05
Company Information
Active Ingredients
Strength: 150 iu/ml
Detailed Information
Contraindications
**4 CONTRAINDICATIONS** None.
Indication Information
**1 INDICATIONS AND USAGE** HYPERRAB is a human rabies immune globulin indicated for postexposure prophylaxis, along with rabies vaccine, for all persons suspected of exposure to rabies. Limitations of Use Persons who have been previously immunized with rabies vaccine and have a confirmed adequate rabies antibody titer should receive only vaccine.1–3 For unvaccinated persons, the combination of HYPERRAB and vaccine is recommended for both bite and nonbite exposures regardless of the time interval between exposure and initiation of postexposure prophylaxis.1–3 Beyond 7 days (after the first vaccine dose), HYPERRAB is not indicated since an antibody response to vaccine is presumed to have occurred. * * * **15 REFERENCES** 1. Centers for Disease Control and Prevention. Human rabies prevention – United States, 2008: Recommendations of the Advisory Committee on Immunization Practices. MMWR. 2008;57(RR03):1–26, 28. 2. World Health Organization. WHO Expert Consultation on Rabies: Second report. 2013. WHO technical report series, No. 982. 3. Centers for Disease Control and Prevention. Use of a reduced (4-dose) vaccine schedule for postexposure prophylaxis to prevent human rabies. Recommendations of the Advisory Committee on Immunization Practices. MMWR. 2010;59(RR02):1–9. Erratum in: MMWR 2010;59(16):493.